New skin test could reveal hidden cancer risks

NCT ID NCT07112287

Recruiting now Knowledge-focused Sponsor: Christopher Reilly Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new genetic test called the MyeloGen Gene Panel to see if it can quickly and reliably find inherited risks for myeloid cancers (a type of blood cancer). Researchers will take a small skin sample from 200 adults with these cancers and analyze it for genetic changes. The goal is to see if results can be returned within 10 weeks, which could help doctors better understand and manage the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MyeloGen Gene Panel (genetic test using skin fibroblasts)
What this could lead to: If successful, this could make it easier to identify people with inherited risks for myeloid cancers, potentially guiding earlier monitoring or treatment.
What could go wrong: This is an early feasibility study, not a treatment trial. The test may not be faster or more reliable than current methods, and results may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENETIC PREDISPOSITION TO DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited disease susceptibility myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENETIC PREDISPOSITION TO DISEASE MYELOID HEMATOLOGICAL MALIGNANCIES MYELOID MALIGNANCY

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.